William H. Rastetter, Ph.D., Executive Chairman

William H. Rastetter, Ph.D., was formerly Chairman and Chief Executive Officer of IDEC Pharmaceuticals. Dr. Rastetter was appointed Chairman of the Board of Directors of IDEC on May 22, 1996. He served as President and Chief Executive Officer of IDEC from December 1986 until January 2002, when he turned over the title of President to William Rohn. Dr. Rastetter was also Chief Financial Officer of IDEC from 1988 to 1993. He served as a Director of IDEC since 1986. From 1984 to 1986, Dr. Rastetter was Director of Corporate Ventures at Genentech. From 1982 to 1984, he served in a scientific capacity at Genentech, directing the Biocatalysis and Chemical Sciences groups. From 1975 to 1982, Dr. Rastetter held various positions at the Massachusetts Institute of Technology. He received his Ph.D. in Chemistry from Harvard University in 1975.

In addition to his position at Biogen Idec, Dr. Rastetter serves as a Director on the board of Illumina, Inc., a company that develops parallel, miniaturized and flexible biosensors. He also serves on the California Healthcare Institute (CHI). In addition, he is the R. B. Woodward Visiting Scholar of the Department of Chemistry and Chemical Biology at Harvard University.

James C. Mullen, Chief Executive Officer

James C. Mullen was formerly Chairman of the Board and Chief Executive Officer of Biogen. He was named Chairman of the Board of Directors in July 2002, after being named President and Chief Executive Officer of Biogen in June 2000. Mr. Mullen joined Biogen in 1989 as Director, Facilities and Engineering. He was named Vice President, Operations, in 1992. From 1996 to1999, Mr. Mullen served as Vice President, International, with responsibility for building all Biogen operations outside North America.

From 1984 to 1988, Mr. Mullen held various positions at SmithKline Beckman Corporation (now GlaxoSmithKline plc). He holds a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute and a M.B.A. from Villanova University.

Mr. Mullen serves on the Board of Trustees of Rensselaer Polytechnic Institute, the Board of Directors of the Biotechnology Industry Organization (BIO) and is co-chair of Cambridge Family and Children’s Service Capital Campaign Steering Committee.

Burt A. Adelman, M.D., Executive Vice President, Development

Burt A. Adelman, M.D. was previously Executive Vice President, Research and Development at Biogen, a position he attained in October 2001. Prior to that time, Dr. Adelman was Vice President of Medical Research. He began his career with Biogen in 1991, joining the company as Director of Medical Research, and has held positions of increasing responsibility including Vice President, Regulatory Affairs, and Vice President, Development Operations. In that role he oversaw the Preclinical Development, Medical Operations and Regulatory Affairs groups. Since 1992, Dr. Adelman has served as a lecturer at Harvard Medical School. He is a member of the Board of Directors for the New England Healthcare Institute (NEHI).

Thomas J. Bucknum, Esq., Executive Vice President and General Counsel

Thomas J. Bucknum was previously Executive Vice President and General Counsel at Biogen. He joined Biogen in 1996 as Chief Corporate Counsel and was appointed Vice President and General Counsel in 1999. Previously, he was Senior Vice President and General Counsel for DuPont Merck Pharmaceutical Company from 1990-95, responsible for Legal, Government and Public Affairs. Mr. Bucknum held a number of positions with E.I. DuPont de Nemours and Company, including Director of Regulatory Affairs and Quality Assurance for Medical Products; Marketing Director for Agricultural Products, Europe, Middle East and Africa; European Counsel; and Patent Counsel for Pharmaceuticals and Agricultural Products. He holds a B.S. in Pharmacy, an M.S. in Pharmacology, and a J.D. from Temple University.

John M. Dunn, Executive Vice President, New Ventures

John M. Dunn was previously Senior Vice President, Legal and Compliance, and General Counsel of IDEC Pharmaceuticals. He led IDEC’s legal and compliance departments and served as a member of the company’s senior management team. Previously, Mr. Dunn had been a partner with Pillsbury Winthrop LLP and co-leader of the firm’s Biotech, Pharmaceuticals and Healthcare Industry Team. He has been practicing law for nearly 25 years, specializing in corporate and business representation of public and private companies.

Nabil Hanna, Ph.D., Executive Vice President, Research

Nabil Hanna, Ph.D., was previously Chief Scientific Officer of IDEC Pharmaceuticals. Dr. Hanna joined IDEC in February 1990 as Vice President, Research and Preclinical Development. In August 1993, Dr. Hanna was appointed Senior Vice President of R&PD and in May 1998, Dr. Hanna was promoted to Chief Scientific Officer. From 1981 to 1990, Dr. Hanna served as Associate Director and then Director of the Department of Immunology at SmithKline Beecham, focusing on autoimmune and chronic inflammatory diseases. From 1978 to 1981, he was a research scientist at the NCI-Frederick Cancer Research Center, where he studied the role of immune system cells in host defenses against cancer. From 1973 to 1978, Dr. Hanna was a lecturer in the Department of Immunology at the Hebrew University Medical School in Israel, where he received his Ph.D. in Immunology. Pursuant to the company’s agreement with CNI, Dr. Hanna is a director of CNI, now known as Cytokine PharmaSciences.

Peter N. Kellogg, Executive Vice President, Finance and Chief Financial Officer

Peter N. Kellogg was formerly Executive Vice President, Finance and CFO of Biogen. He joined Biogen in 2000 from PepsiCo Inc., where he was most recently Senior Vice President, PepsiCo E-Commerce. From 1987 to 2000, he served in a variety of senior financial, international and general management positions at PepsiCo, including Vice President and General Manager-Pepsi, South Franchise Business Unit; Vice President and Chief Financial Officer, Central/Eastern Europe and Russia, Pepsi-Cola International; Vice President and Chief Financial Officer, Frito-Lay Latin America; and Senior Vice President and Chief Financial Officer, Frito-Lay International. Prior to joining PepsiCo, Mr. Kellogg was a senior consultant with Arthur Andersen & Co. and Booz Allen & Hamilton. He received a B.S.E. in Civil Engineering from Princeton University and an M.B.A. from The Wharton School.

Connie L. Matsui, Executive Vice President, Corporate Strategy and Communication

Connie L. Matsui was previously Senior Vice President, Planning and Resource Development of IDEC Pharmaceuticals. Ms. Matsui joined the company in November 1992 as Senior Director, Planning and Resource Development with primary responsibility for strategic planning and human resources. In December 1994, Ms. Matsui was promoted to Vice President, Planning and Resource Development. In 2000 Ms. Matsui was promoted to Senior Vice President, overseeing investor relations, corporate communications, human resources, project management and strategic planning. From 1977 to 1991, she served in a variety of marketing and general management positions at Wells Fargo Bank, including Vice President and Manager responsible for Consumer Retirement Programs and Vice President and Manager in charge of company-wide Employee Relations and Communications. Ms. Matsui has been active on a number of not-for-profit boards and currently serves as the National President of the Girl Scouts of the USA. Ms. Matsui received her B.A. and M.B.A. from Stanford University.

William R. Rohn, Executive Vice President and Chief Operating Officer

William R. Rohn was previously President and Chief Operating Officer of IDEC Pharmaceuticals. He joined IDEC in August 1993 as Senior Vice President, Commercial and Corporate Development. Mr. Rohn was appointed Senior Vice President, Commercial Operations in April 1996 and was promoted to Chief Operating Officer in May 1998. In January 2002, Mr. Rohn was further promoted to President.

Prior to joining IDEC, Mr. Rohn was employed by Adria Laboratories, now part of Pharmacia Corporation, from 1984 until 1993, most recently as Senior Vice President of Sales and Marketing with responsibilities for strategic and commercial partnerships as well as sales and marketing functions in the United States. Prior to Adria, Mr. Rohn held marketing and sales management positions at Abbott Laboratories, Warren-Teed Pharmaceuticals, Miles Laboratories and Mead Johnson Laboratories. Mr. Rohn received a B.A. in Marketing from Michigan State University.

Currently, Mr. Rohn serves on the Board of Directors of Pharmacyclics, a pharmaceutical company developing energy-potentiating drugs to improve radiation therapy and chemotherapy of cancer, and to enable or improve the photodynamic therapy of certain cancers and atherosclerotic cardiovascular disease. In April 2002, Mr. Rohn joined the Board of Directors of Cerus Corporation. Cerus is developing medical systems and therapeutics based on its proprietary Helinx® technology for controlling biological replication.

Craig E. Schneier, Ph.D., Executive Vice President, Human Resources

Craig E. Schneier, Ph.D., was previously Executive Vice President, Human Resources of Biogen. Dr. Schneier joined Biogen in 2001 as Senior Vice President, Strategic Organization Design and Effectiveness, after having served as an external consultant to the company for eight years. Prior to joining Biogen, Dr. Schneier was president of his own management consulting firm in Princeton, NJ, where he provided consulting services to over 70 of the Fortune 100 companies, as well as several of the largest European and Asian firms. He also led consulting efforts at Organizational Dynamics in Boston, and was managing partner at Sibson & Company, a consulting firm in Princeton, NJ. Dr. Schneier held a tenured professorship at the University of Maryland’s Smith School of Business and has held teaching positions at the business schools of the University of Michigan and Columbia University. He currently teaches at the Tuck School of Business, Dartmouth College.